PALB2: research reaching to clinical outcomes for women with breast cancer.

There is still very little data and no evidence supporting an association between PALB2 mutations and prostate cancer risk [ 13 , 36 – 39 ] although several pedigrees have been presented and a possible trend toward aggressive disease in carriers has been noted [ 39 ]. iCOGS measured PALB2 (c.1592delT, p.Leu531Cysfs and c.3113G > A, p.Trp1038*) in 22,301 prostate cancer cases and 22,320 controls and found no evidence for association with prostate cancer risk OR 2.06, 95 % CI 0.59–7.11, p = 0.24 and OR 0.49, 95 % CI, 0.18–1.36, p = 0.16 respectively.

also in 948 other papers